

1 **Viral cultures, Polymerase Chain Reaction Cycle Threshold Values and**  
2 **Viral Load Estimation for SARS-CoV-2 Infectious Potential Assessment**  
3 **in Hematopoietic Stem Cell and Solid Organ Transplant Patients: A**  
4 **Systematic Review.**

5 Tom Jefferson<sup>1</sup>, Elizabeth A. Spencer<sup>2</sup>, Elena C. Rosca<sup>3</sup>, Susanna Maltoni<sup>4</sup>, Jon Brassey<sup>5</sup>, Igho J.  
6 Onakpoya<sup>1</sup>, Annette Plüddemann<sup>2</sup>, David H. Evans<sup>6</sup>, John M. Conly<sup>7</sup>, Carl J. Heneghan<sup>2</sup>.

7 <sup>1</sup>Department for Continuing Education, University of Oxford, UK

8 <sup>2</sup>Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences,  
9 University of Oxford, UK

10 <sup>3</sup>Victor Babes University of Medicine and Pharmacy, Timisoara, Romania

11 <sup>4</sup>Division of Research and Innovation, IRCCS Azienda Ospedaliero-Universitaria di Bologna,  
12 Bologna, Italy

13 <sup>5</sup>Trip Database Ltd, Newport, UK

14 <sup>6</sup>Li Ka Shing Institute of Virology and Dept. of Medical Microbiology & Immunology, University  
15 of Alberta, Canada

16 <sup>7</sup>Departments of Medicine, Microbiology, Immunology & Infectious Diseases, and Pathology &  
17 Laboratory Medicine, Synder Institute for Chronic Diseases and O'Brien Institute for Public

18 Health, Cumming School of Medicine, University of Calgary and Alberta Health Services,

19 Calgary, Canada.

20

## 21 **Abstract**

22 Background: Organ transplant recipients are at increased vulnerability to SARS-CoV-2 due to  
23 immunosuppression and may pose a continued transmission risk especially within hospital  
24 settings. Detailed case reports including symptoms, viral load and infectiousness, defined by the  
25 presence of replication-competent viruses in culture, provide an opportunity to examine the  
26 relationship between clinical course, burden and contagiousness, and provide guidance on  
27 release from isolation.

28 Objectives: We performed a systematic review to investigate the relationship in transplant  
29 recipients between serial SARS-CoV-2 RT-PCR cycle threshold (Ct) value or cycle of  
30 quantification value (Cq), or other measures of viral burden and the likelihood and duration of  
31 the presence of infectious virus based on viral culture including the influence of age, sex,  
32 underlying pathologies, degree of immunosuppression, and/or vaccination on this relationship.

33 Methods: We searched LitCovid, medRxiv, Google Scholar and WHO Covid-19 databases, from 1  
34 November 2019 until 31 December 2021. We included studies reporting relevant data for  
35 transplantees with SARS-CoV-2 infection: results from serial RT-PCR testing and viral culture  
36 data from the same respiratory samples. We assessed methodological quality using five criteria,  
37 and synthesised the data narratively and graphically.

38 Results: We included 9 case reports and case series reporting on 30 transplantees. We observed  
39 a relationship between proxies of viral burden and likelihood of shedding replication-  
40 competent SARS-CoV-2 particles. Two individuals shed replication-competent particles over 100  
41 days after infection onset. Lack of standardisation of testing and reporting precludes

42 establishing a viral burden cutoff. Most transplantees stopped shedding competent particles  
43 when the RT-PCR cycle threshold was above 30, but there are differences across platforms.

44 **Conclusions**

45 Viral burden is a reasonable proxy for infectivity when considered within the context of the  
46 clinical status of each patient. Standardised study design and reporting are essential to avoid  
47 research waste and generate guidance based on an increasing evidence base.

48

49

50

51

52

53 **Keywords**

54 COVID-19; SARS-CoV-2; transmission; organ transplants; viral culture; polymerase chain  
55 reaction; viral load; cycle threshold calibration; infectivity

56

## 57 Introduction

58 Haematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients have  
59 significant immunosuppression, affecting both cellular and humoral immunity, and less  
60 favourable outcomes with Severe Acute Respiratory Virus Syndrome 2 (SARS-CoV-2) infection,  
61 due to the immunosuppression and/or to pre-existing comorbidities<sup>1</sup>. Immunosuppression  
62 associated with transplantation places patients at risk for prolonged carriage and shedding of  
63 several respiratory viruses<sup>2</sup>. However, identification of respiratory viral shedding, recently by  
64 reverse transcriptase polymerase chain reaction (RT-PCR), does not always correlate with the  
65 presence of replication-competent virus<sup>3</sup>. Accordingly, we sought to perform a systematic  
66 review of RT-PCR testing and viral culture of SARS-CoV-2, focussing on people receiving solid  
67 organ or hematopoietic stem cell transplants, following our published protocol<sup>4</sup>.

68 Our research questions were:

- 69 1. What is the relationship between serial SARS-CoV-2 RT-PCR cycle threshold (Ct) value or  
70 cycle of quantification value (Cq), or other measures of viral burden?
- 71 2. What is the likelihood and duration of the presence of infectious virus based on viral  
72 culture, among transplant recipients with SARS-CoV-2 infection?
- 73 3. What is the influence of age, sex, underlying pathologies and degree of  
74 immunosuppression on infectiousness of SARS-CoV-2?
- 75 4. What is the relationship of vaccination status on infectiousness with SARS-CoV-2?

76 We included studies reporting serial Cts from sequential RT-PCR testing or other measures of

77 viral burden such as RNA gene copies of respiratory samples (from nasopharyngeal or throat  
78 specimens) along with viral culture data on the same samples, from patients about to receive a  
79 transplant or who were post-transplant, with SARS-CoV-2 infection.

## 80 **Methods**

### 81 **Search Strategy**

82 We searched the following electronic databases: LitCovid, medRxiv, Google Scholar and the  
83 WHO Covid-19 database from November 2019 until December 31, 2021. No language  
84 restrictions were applied.

85 The literature search terms were: (coronavirus OR covid-19 OR SARS-CoV-2) AND  
86 (immunosuppressed OR immunocompromised OR transplant OR immunosuppression OR  
87 "immune deficient" OR HIV) AND (CPE OR "cytopathic effect" OR "Viral culture" OR "virus  
88 culture" OR vero OR "virus replication" OR "viral replication" OR "cell culture" or "viral load" OR  
89 "viral threshold" OR "log copies" OR "cycle threshold").

### 90 **Screening**

91 Four reviewers independently screened titles and abstracts to identify studies for consideration  
92 of full text. Full text screening was performed in duplicate and disagreements arbitrated by a  
93 third reviewer.

### 94 **Inclusion criteria**

95 We included studies reporting serial Cts from sequential RT-PCR testing, or RNA gene copies of

96 respiratory samples (nasopharyngeal, throat, sputum, bronchoalveolar lavage, endotracheal  
97 tube secretions) AND viral culture data from the same samples from patients about to receive a  
98 transplant or post transplant with SARS-CoV-2 infection. We included primary studies providing  
99 they reported sufficient information to extract quantitative data on the PCR testing and the  
100 viral culture for each included individual. Studies that included transplant and non-transplant  
101 patients were included if we could ascertain the results separately. Studies reporting only in  
102 poster or abstract form were excluded. Reviews were excluded but the reference lists screened  
103 for potential relevant primary studies.

#### 104 **Exclusion criteria**

105 We excluded studies using post-mortem samples only and non-respiratory samples only. We  
106 did not include studies of non-transplant patients or those not attempting viral cultures.

#### 107 **Data extraction**

108 One reviewer extracted data, which was independently checked by a second reviewer.  
109 Disagreements were arbitrated by a third reviewer. Data were extracted on study type and  
110 study characteristics, including population, setting, sampling and laboratory methods, clinical  
111 information, prescribed treatments, vaccination status, laboratory findings, and clinical  
112 outcomes. For three studies we sought clarification from the corresponding authors.

#### 113 **Quality assessment**

114 We assessed the quality of included studies according to five criteria:

115 1. Were the criteria for diagnosing a case clearly reported and appropriate?

- 116 2. Was the reporting of patient/population characteristics including clinical symptoms,  
117 treatments with degree of immunosuppression and outcomes adequate?
- 118 3. Was the study period, including follow-up, sufficient to adequately assess any potential  
119 relationship between viral burden measures and likelihood of producing replication-  
120 competent virus and the rise in neutralising antibodies?
- 121 4. Were the methods used to obtain RT-PCR results replicable, generalisable and  
122 appropriate? We considered that each study should establish the relationship between  
123 their Ct values and the target gene copy number, using internal standards.
- 124 5. Were the methods used to obtain viral culture results replicable and appropriate? We  
125 considered the methods used should, at a minimum, include a description of specimen  
126 sampling and management, preparation, media and cell line used, exclusion of  
127 contamination or co-infection (use of good controls and appropriate antibacterials and  
128 antimycotics and possible use of gene sequencing if available), and results of inspection  
129 of culture.

### 130 **Data reporting and pooling**

131 We reported study flow according to PRISMA reporting standards<sup>5</sup>. We reported study  
132 characteristics including age, sex, clinical symptoms, treatments and events in the participants  
133 in tabular form. We presented data on disease burden measures and on viral culture in tabular  
134 form. For studies reporting more than one patient participant, data were extracted related to  
135 each participant if available. We plotted median, interquartile ranges and outliers for viral



136 culture results in relation to the duration of symptoms, and individual study plots to day 120 of  
137 viral culture results and cycle thresholds.

138 We were unable to pool the data on PCR cycle counts/RNA log copies and viral culture, due to a  
139 lack of detailed information on laboratory practices, assays and because of the absence of  
140 internal controls in some studies, and heterogeneous sampling. We therefore reviewed the  
141 studies narratively, and where possible reported the results graphically.

## 142 **Results**

143 The literature search identified 12,988 titles for screening. Of these 63 underwent full-text  
144 review. 54 studies were excluded after full-text analysis: reasons are reported in the list of  
145 excluded studies (see Supplementary File. List of excluded studies.)

146 Of the nine included studies (Figure 1<sup>5</sup>) they reported data for 30 transplant patients (7 females  
147 and 23 males): renal (21), cardiac (5), bone marrow transplant (1), liver (2), bilateral lung (1).

148 The 30 patients were in six countries: Saudi Arabia<sup>6</sup>, France<sup>7 8</sup>, Germany<sup>9 10 11</sup>, Austria<sup>12</sup>,  
149 Denmark<sup>13</sup>, and Canada<sup>14</sup>, and were aged between 26 and 75 years old.

150 28 were infected with SARS-CoV-2 post transplant: 21 patients in 3 studies had had kidney  
151 transplant<sup>6 7 11</sup>, 5 patients in 4 studies had had a cardiac transplant<sup>6 9 14 8</sup>, 1 previous bone  
152 marrow transplant for multiple myeloma<sup>13</sup>, 1 liver transplant<sup>13</sup>. Two patients were infected  
153 with SARS-CoV-2 and subsequently underwent transplant: 1 liver transplant<sup>10</sup>, 1 patient had  
154 bilateral lung transplantation after a SARS-CoV-2 infection that severely affected the lungs<sup>12</sup>.

155 Typically, patients received a mixture of antivirals and immune suppressants, as reported in

156 Table 1. The clinical course of COVID-19 varied widely amongst the included patients, from mild  
157 COVID-19 related symptoms to severe pneumonia and lung failure; none of the patients died.  
158 Prescribed treatments reflected the variation in severity.

### 159 **Quality Assessment**

160 Table 2 reports study quality based on five criteria. Three studies<sup>14 8 11</sup> met all five criteria.  
161 Follow-up was judged adequate in all studies; in eight studies the reporting of patient  
162 characteristics was sufficiently comprehensive<sup>7 9 12 10 13 14 8 11</sup> and clinical information was  
163 missing for one study<sup>6</sup>. Case definition was missing or unclear in three studies<sup>6 9 13</sup>), and  
164 methods for RT- PCR testing were unclear in two studies<sup>9 12</sup>. The methods used for viral culture  
165 were unclear for four studies<sup>6 9 12 10</sup> and one study reported using a cell line that has not  
166 typically been used to demonstrate SARS-CoV-2 growth - Buffalo green monkey kidney (BGMK)  
167 cell line<sup>7</sup>.

### 168 **Results of the studies**

169 The results are reported in Table 1 and Table 3. The clinical course of infection was highly  
170 variable (Tables and 1 and 3, and Figures 2 and 3). Sampling schedules varied between studies,  
171 with no regular timetable of testing taking place, so results for PCR and viral culture are  
172 available for different time points in a patient's clinical course and with different gaps in time  
173 between samples being taken.

174 In response to our first study question on the relationship between proxy indicators of viral  
175 burden and infectiousness, the data from Figures 2 and 3 and Table 3 indicate a relationship

176 between viral burden and probable infectiousness. The data suggests that earlier symptom  
177 onset is related to the likelihood of shedding replication-competent virus (Figure 2). The median  
178 for a positive culture from onset of symptoms was 16 days (IQR 9 to 27; range 1-105, n = 45  
179 cultures performed). The median for a negative culture was 41 days (IQR 21 to 60; range 1-120,  
180 n = 96 cultures performed).

181 Five patients reported by Alshukairi et al were all culture-negative; this was in samples taken on  
182 days 9,12, 17,18 and day 26 since symptom onset, respectively <sup>6</sup>.

183 Eight kidney transplant patients described by Benotmane and colleagues had positive viral  
184 cultures <sup>7</sup>.

185 For six patients we could identify the duration of probable infectiousness, which ranged from 8  
186 days (patient 5: day 1 to 8) to 32 days (patient 7: day 7 to 38). Four patients were infectious  
187 with reported Cts > 30 based on the individual platforms that were used to perform the Cts.

188 Rajakumar et al<sup>14</sup> described two cardiac transplant patients: viral culture found replication-  
189 competent virus in samples from one patient on day 16 and in samples from the other patient  
190 on day 4 and repeatedly up to day 27, after which all viral cultures were negative<sup>14</sup>. For each  
191 patient, viral culture was negative (i.e. no replication-competent virus observed) in samples  
192 with PCR cycle counts of over 25. Within the samples giving positive viral cultures, the PCR  
193 results showed that the cycle threshold for the N gene was lower than for the E gene by an  
194 average of 5.4 Ct values.

195 In the study by Niyonkuru et al, the duration of infectiousness in the two patients, as indicated

196 by replication-competent virus, was 8 and 9 days (Figure 3)<sup>13</sup>. A cardiac transplant patient  
197 described by Tarhini<sup>8</sup> and colleagues tested culture-positive with a Ct of 23 on day 103; all other  
198 viral cultures were negative from samples with PCR Cts of 18 to over 40<sup>8</sup>.

199 Weigang et al<sup>11</sup> described a kidney transplant patient who experienced three hospital  
200 admissions. During the first one (day zero to day 72), 19 RT-qPCR tests were performed, and  
201 alongside that viral culture was performed, showing 8/19 positive cultures (Ct values ranging  
202 from 15 to 25) and 11/19 negative (Ct values from 25 to 30). The patient was culture positive  
203 again on day 105 (Ct of 23). After re-admission at day 140 the patient was still RT-qPCR positive,  
204 but with viral culture negative; he was treated for 10 days (days 141-149) with remdesivir.  
205 Subsequently, negative RT-qPCR tests until day 189 and failed virus isolation attempts  
206 suggested that the infection had resolved<sup>11</sup>.

207 A heart transplant patient described by Decker<sup>9</sup> and coworkers had a positive viral culture on  
208 day 18 and day 21 with 6.2 and 6.5 log<sub>10</sub> copies/ml.<sup>9</sup>

209 Although the dataset was limited, we observe an inverse relationship (Ct/Cq) or direct  
210 relationship (log copies): the viral burden indicated by these methods correlated with  
211 infectiousness, as shown by the ability to produce replication-competent virus in culture. The  
212 presence of replication-competent virus reflects one of the highest grades of evidence  
213 supporting the capability for forward transmission of SARS-CoV-2<sup>15, 16</sup>.

214 The robustness of the correlation is difficult to assess because laboratory methods differ; it was  
215 not possible to pool the data to produce a summary cut-off value for infectiousness, due to  
216 these variations and due to varying time windows for sampling from patients (see Figure 2 and

217 Table 3.)

218 In response to our second research question (on the likelihood and duration of infectiousness  
219 among transplant recipients with SARS-CoV-2 infection) the data indicate that regardless of  
220 differences in laboratory practices, observed prolonged shedding of replication-competent  
221 virus is associated with alternating increases and decreases of viral burden over time, which in  
222 some cases may be up to around 100 days<sup>8 11</sup>.

223 The viral load estimates are affected by administration of courses of anti-viral treatment  
224 including remdesivir. See Figures 2a (Cts/Cqs) and 2b (log copies).

225 Responding to our third research question (the influence of age, sex, underlying pathologies  
226 and degree of immunosuppression on infectiousness): at present the heterogeneity and limited  
227 amount of the available data preclude answering this question.

228 We are unable to answer our fourth and final research question on the relationship of  
229 vaccination status on infectiousness because no study reported on vaccination status for these  
230 transplant patients.

231

## 232 Discussion

233 This review included 9 reports of studies using viral culture and RT-qPCR testing among 30  
234 transplant patients with immunosuppressive treatment who experienced COVID-19 infection.  
235 The evidence indicates a relationship between indicators of viral burden (Ct, Cq or RNA log  
236 copies) and probable infectiousness as indicated by the presence of replication-competent  
237 virus. Gaps in the data remain due to variable methods and reporting and establishing summary  
238 estimates of the relationship has not been possible. The data show a long term rise and fall of  
239 viral burden associated with the likelihood of infectiousness that in some transplant patients  
240 appears to be a sequential pattern of going in and out of infectiousness. Replication-competent  
241 virus was most commonly observed in samples with PCR Ct values under 25; one study was an  
242 exception to this by reporting viable virus at Ct>30, but the use of a cell line not typically used  
243 for SARS-CoV-2 isolation makes interpretation unclear<sup>7</sup>. The duration of viral RNA shedding was  
244 variable, with the longest duration reported at 105 days<sup>11</sup>.

245 Regarding our second review question on the influence of patient variables on the likelihood of  
246 the presence of infectious SARS-CoV-2, the included studies showed substantial heterogeneity;  
247 some had missing data or few cultures available, and meta-analysis or pooling was not possible.

248 Variability in the clinical course of SARS-CoV-2 infection among transplant recipients has been  
249 reported, including observed prolonged viral shedding<sup>17</sup>. Antiviral drugs may impact on these  
250 observations, especially symptoms and viral burden.<sup>18</sup>

251 Two well-designed studies on immunosuppressed patients, which we were unable to include  
252 because disaggregated data solely for transplant patients were not fully available, support our

253 conclusions<sup>19, 20</sup>. While this review is limited to transplant patients, evidence suggests similar  
254 prolonged viral cultures are found in immunosuppressed cancer patients. We plan to perform a  
255 further review in this group analysing the type of cancer and the impact of immunotherapies on  
256 viral culture findings.

257 The transplant patient population is of particular importance: clinicians need guidance as to  
258 when to release the patient from quarantine or isolation, given the heavy burden of  
259 immunosuppression. We have tried to narrow the uncertainty and offer some general guidance  
260 as to when patients are unlikely to be shedding replication-competent viral particles, but  
261 clinical assessment of each patient must inform that decision because each patient and setting  
262 is different.

263 The strengths of this review are that we followed our published protocol, entailing rigorous  
264 literature searches, double checked data extraction and quality assessment, and a high level of  
265 clinical and epidemiological expertise input to deliberate the findings. Limitations include the  
266 small number of studies with viral culture and serial viral load estimates among transplant  
267 patients, high variability in study design and reporting and impossibility to pool results due to  
268 the well-known variability in sensitivity across essays<sup>21</sup>.

269 Case series are conventionally considered low in the evidence hierarchy, as they may entail  
270 inherent bias in the selection of study participants and therefore have limited generalisability;  
271 however, here they are essential in providing the detailed reports needed for this unusual  
272 patient group. The case reports included here comprise some of the most detailed longitudinal  
273 reports of this patient group for whom data are needed. The evidence base is limited, however,

274 by heterogeneous design and reporting within the studies with, for example, different  
275 observation windows for reporting of viral burden and culturability or clinical characteristics of  
276 patients.

277 In addition to providing appropriate care for the individual patient, ongoing transmission of  
278 SARS-CoV-2 is a concern, and immunosuppressed individuals may pose a challenge by  
279 experiencing prolonged carriage of the virus that could lead to forward transmission. Based on  
280 our findings we would offer the following general guidance to clinicians:

281 Physicians who are experienced with these immunosuppressed patient populations should  
282 work with public health to direct their isolation and quarantine requirements. Patients with  
283 immunosuppressive treatment following solid organ or stem cell transplantation should be  
284 isolated until at least two consecutive respiratory specimens collected  $\geq 24$  hours apart  
285 demonstrate a rising RT-PCR Ct (i.e. indicating diminishing viral burden). After discharge, they  
286 should be closely followed up for SARS-CoV-2 infection for several weeks to months, depending  
287 on the individual clinical scenario.

288 For obtaining data, standardisation of methods is needed: each laboratory should use  
289 consistently applied platforms with suitable internal standards to calibrate the relationship  
290 between Ct and genome copy in these patient populations.

291 Publication of results of case series or other longitudinal study should be reported in a  
292 standardised format to avoid loss of data. We suggest observation windows should be within a  
293 short range of 3 to 7 days during the acute periods post-transplantation and during periods of  
294 rejection when higher doses of immunosuppressants are employed, depending on clinical



295 circumstances. Each observation window should include a summary of symptoms and  
296 interventions, the reporting of PCR cycle threshold and, for samples with Ct below 30, attempts  
297 at viral culture if available. Description of patients should include past medical histories and  
298 details of treatments received. Observed drug interactions should be highlighted. Reasons for  
299 admission, discharge and changes in isolation should be clearly reported. To investigate the  
300 duration of viral shedding, studies should report the time between the first positive and the  
301 first negative viral cultures.

302 With additional data gathering and standardisation of methods, it will be possible for transplant  
303 physicians to develop evidence-based approaches to dealing with these patients for the benefit  
304 of the patients and their families and the community at large.

305

### 306 **Funding**

307 This work is supported by the National Institute of Health Research School for Primary  
308 Care Research [Project 569] and by the University of Calgary.

### 309 **Author contributions**

310 TJ, CH and JC designed the study. JB performed the literature searches. JB, TJ, SM, ER and  
311 ES, screened the studies for eligibility and performed data extraction. Additional expertise  
312 on clinical and laboratory issues was given by DE, JC, SM and ER. CH generated the data  
313 figures. All authors contributed to interpreting and writing up the results and conclusions.

### 314 **Acknowledgements**

315 We gratefully acknowledge the contributions of Drs Mina Kamboj and Jeroen van Kampen  
316 who provided additional data from their studies and helped us to progress this work.  
317

318

319 **Conflict of interest statements**

320 TJ's competing interests are accessible at: [https://restoringtrials.org/competing-interests-tom-](https://restoringtrials.org/competing-interests-tom-jefferson)  
321 [jefferson](https://restoringtrials.org/competing-interests-tom-jefferson)

322 CJH holds grant funding from the NIHR, the NIHR School of Primary Care Research, the NIHR  
323 BRC Oxford and the World Health Organization for a series of Living rapid review on the modes  
324 of transmission of SARs-CoV-2 reference WHO registration No2020/1077093. He has received  
325 financial remuneration from an asbestos case and given legal advice on mesh and hormone  
326 pregnancy tests cases. He has received expenses and fees for his media work including  
327 occasional payments from BBC Radio 4 Inside Health and The Spectator. He receives expenses  
328 for teaching EBM and is also paid for his GP work in NHS out of hours (contract Oxford Health  
329 NHS Foundation Trust). He has also received income from the publication of a series of toolkit  
330 books and for appraising treatment recommendations in non-NHS settings. He is Director of  
331 CEBM and is an NIHR Senior Investigator.

332 DE holds grant funding from the Canadian Institutes for Health Research and Li Ka Shing  
333 Institute of Virology relating to the development of Covid-19 vaccines as well as the Canadian  
334 Natural Science and Engineering Research Council concerning Covid-19 aerosol transmission.  
335 He is a recipient of World Health Organization and Province of Alberta funding which supports  
336 the provision of BSL3-based SARS-CoV-2 culture services to regional investigators. He also holds  
337 public and private sector contract funding relating to the development of poxvirus-based Covid-  
338 19 vaccines, SARS-CoV-2-inactivation technologies, and serum neutralization testing.

339 JMC holds grants from the Canadian Institutes for Health Research on acute and primary care  
340 preparedness for COVID-19 in Alberta, Canada and was the primary local Investigator for a  
341 *Staphylococcus aureus* vaccine study funded by Pfizer for which all funding was provided only to  
342 the University of Calgary. He is co-investigator on a WHO funded study using integrated human  
343 factors and ethnography approaches to identify and scale innovative IPC guidance  
344 implementation supports in primary care with a focus on low-resource settings and using drone  
345 aerial systems to deliver medical supplies and PPE to remote First Nations communities during  
346 the COVID-19 pandemic. He also received support from the Centers for Disease Control and  
347 Prevention (CDC) to attend an Infection Control Think Tank Meeting. He is a member and Chair  
348 of the WHO Infection Prevention and Control Research and Development Expert Group for  
349 COVID-19 and a member of the WHO Health Emergencies Programme (WHE) Ad-hoc COVID-19  
350 IPC Guidance Development Group, both of which provide multidisciplinary advice to the WHO  
351 and for which no funding is received and from which no funding recommendations are made  
352 for any WHO contracts or grants. He is also a member of the Cochrane Acute Respiratory  
353 Infections Working Group.

354 JB is a major shareholder in the Trip Database search engine ([www.tripdatabase.com](http://www.tripdatabase.com)) as well as  
355 being an employee. In relation to this work Trip has worked with a large number of  
356 organisations over the years, none have any links with this work. The main current projects are  
357 with AXA and SARS-CoV-2 (WHO Registration 2020/1077093-0) and is part of the review group  
358 carrying out rapid reviews for Collateral Global. He worked on Living rapid literature review on  
359 the modes of transmission of SARS-CoV-2 and a scoping review of systematic reviews and meta-

360 analyses of interventions designed to improve vaccination uptake (WHO Registration  
361 2021/1138353-0).

362 ECR was a member of the European Federation of Neurological Societies (EFNS) / European  
363 Academy of Neurology (EAN) Scientist Panel, Subcommittee of Infectious Diseases (2013 to  
364 2017). Since 2021, she is a member of the International Parkinson and Movement Disorder  
365 Society (MDS) Multiple System Atrophy Study Group, the Mild Cognitive Impairment in  
366 Parkinson Disease Study Group, and the Infection Related Movement Disorders Study Group.  
367 She was an External Expert and sometimes Rapporteur for COST proposals (2013, 2016, 2017,  
368 2018, 2019) for Neurology projects. She is a Scientific Officer for the Romanian National Council  
369 for Scientific Research.

370 AP holds grants from the NIHR School for Primary Care Research.

371 IJO and EAS have no interests to disclose.

372 SM is a pharmacist working for the Italian National Health System since 2002 and a member of  
373 one of the three Institutional Review Boards of Emilia-Romagna Region (Comitato Etico Area  
374 Vasta Emilia Centro) since 2018.

375

376 **References**

377

- 378 1. Jering, K.S., et al., *Excess mortality in solid organ transplant recipients hospitalized with*  
379 *COVID-19: A large-scale comparison of SOT recipients hospitalized with or without*  
380 *COVID-19.* Clin Transplant, 2022. **36**(1): p. e14492. 10.1111/ctr.14492.
- 381 2. Andersen, K.M., et al., *Long-term use of immunosuppressive medicines and in-hospital*  
382 *COVID-19 outcomes: a retrospective cohort study using data from the National COVID*  
383 *Cohort Collaborative.* (2665-9913 (Electronic)).
- 384 3. Fernández-Ruiz, M. and J.M. Aguado, *Severe acute respiratory syndrome coronavirus 2*  
385 *infection in the stem cell transplant recipient - clinical spectrum and outcome.* Curr Opin  
386 Infect Dis, 2021. **34**(6): p. 654-662. 10.1097/qco.0000000000000790.
- 387 4. Jefferson, T., et al., *Viral cultures, PCR Cycle threshold values and viral load estimation*  
388 *for COVID-19 infectious potential assessment in transplant patients: systematic review -*  
389 *Protocol Version 30 December 2021.* medRxiv, 2022: p. 2021.12.30.21268509.  
390 10.1101/2021.12.30.21268509.
- 391 5. Page, M.J., et al., *The PRISMA 2020 statement: an updated guideline for reporting*  
392 *systematic reviews.* BMJ, 2021. **372**: p. n71. 10.1136/bmj.n71.
- 393 6. Alshukairi, A.N., et al., *Test-based de-isolation in COVID-19 immunocompromised*  
394 *patients: Cycle threshold value versus SARS-CoV-2 viral culture.* International Journal of  
395 Infectious Diseases, 2021. **108**: p. 112-115. 10.1016/j.ijid.2021.05.027.
- 396 7. Benotmane, I., et al., *Long-term shedding of viable SARS-CoV-2 in kidney transplant*  
397 *recipients with COVID-19.* American Journal of Transplantation, 2021. **21**(8): p. 2871-  
398 2875. <https://doi.org/10.1111/ajt.16636>.
- 399 8. Tarhini, H., et al., *Long-Term Severe Acute Respiratory Syndrome Coronavirus 2*  
400 *(SARS-CoV-2) Infectiousness Among Three Immunocompromised Patients: From*  
401 *Prolonged Viral Shedding to SARS-CoV-2 Superinfection.* The Journal of Infectious  
402 Diseases, 2021. **223**(9): p. 1522-1527. 10.1093/infdis/jiab075.
- 403 9. Decker, A., et al., *Prolonged SARS-CoV-2 shedding and mild course of COVID-19 in a*  
404 *patient after recent heart transplantation.* Am J Transplant, 2020. **20**(11): p. 3239-3245.  
405 10.1111/ajt.16133.
- 406 10. Niess, H., et al., *Liver transplantation in a patient after COVID-19 - Rapid loss of*  
407 *antibodies and prolonged viral RNA shedding.* Am J Transplant, 2021. **21**(4): p. 1629-  
408 1632. 10.1111/ajt.16349.
- 409 11. Weigang, S., et al., *Within-host evolution of SARS-CoV-2 in an immunosuppressed*  
410 *COVID-19 patient: a source of immune escape variants.* medRxiv, 2021: p.  
411 2021.04.30.21256244. 10.1101/2021.04.30.21256244.
- 412 12. Lang, C., et al., *Lung transplantation for COVID-19-associated acute respiratory distress*  
413 *syndrome in a PCR-positive patient.* The Lancet Respiratory Medicine, 2020. **8**(10): p.  
414 1057-1060. 10.1016/S2213-2600(20)30361-1.
- 415 13. Niyonkuru, M., et al., *Prolonged viral shedding of SARS-CoV-2 in two*  
416 *immunocompromised patients, a case report.* BMC Infectious Diseases, 2021. **21**(1): p.  
417 743. 10.1186/s12879-021-06429-5.
- 418 14. Rajakumar, I.A.-O., et al., *Extensive environmental contamination and prolonged severe*  
419 *acute respiratory coronavirus-2 (SARS CoV-2) viability in immunosuppressed recent*  
420 *heart transplant recipients with clinical and virologic benefit with remdesivir.* (1559-6834  
421 (Electronic)).
- 422 15. Jefferson, T., et al., *Transmission of Severe Acute Respiratory Syndrome Coronavirus-2*  
423 *(SARS-CoV-2) from pre and asymptomatic infected individuals. A systematic review.*  
424 *Clinical Microbiology and Infection,* 2021. <https://doi.org/10.1016/j.cmi.2021.10.015>.

- 425 16. Jefferson, T.H., C.; Spencer, E.; Brassey, J.; Pluddeman, A.; Onakpoya, I.; Evans, D.;  
426 Conly, J. *A Hierarchical Framework for Assessing Transmission Causality of Respiratory*  
427 *Viruses*. PrePrints, 2021. 10.20944/preprints202104.0633.v1.
- 428 17. Marinelli, T., et al., *Prospective Clinical, Virologic, and Immunologic Assessment of*  
429 *COVID-19 in Transplant Recipients*. *Transplantation*, 2021. **105**(10): p. 2175-2183.  
430 10.1097/tp.0000000000003860.
- 431 18. Thornton, C.S., et al., *Prolonged SARS-CoV-2 infection following rituximab treatment:*  
432 *clinical course and response to therapeutic interventions correlated with quantitative viral*  
433 *cultures and cycle threshold values*. *Antimicrob Resist Infect Control*, 2022. **11**(1): p. 28.  
434 10.1186/s13756-022-01067-1.
- 435 19. van Kampen, J.J.A., et al., *Shedding of infectious virus in hospitalized patients with*  
436 *coronavirus disease-2019 (COVID-19): duration and key determinants*. medRxiv, 2020:  
437 p. 2020.06.08.20125310. 10.1101/2020.06.08.20125310.
- 438 20. Aydillo, T., et al., *Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for*  
439 *Cancer*. *New England Journal of Medicine*, 2020. **383**(26): p. 2586-2588.  
440 10.1056/NEJMc2031670.
- 441 21. Bruce, E.A., et al., *Predicting infectivity: comparing four PCR-based assays to detect*  
442 *culturable SARS-CoV-2 in clinical samples*. *EMBO Mol Med*, 2021: p. e15290.  
443 10.15252/emmm.202115290.  
444

445

446 **List of tables and figures.**

447

448 Table 1. Characteristics of transplant patients in included studies.

449

450 Table 2. Quality of included studies.

451

452 Table 3. PCR cycle counts/log copies and viral culture results of included studies.

453

454 Figure 1. PRISMA flow chart of study screening for inclusion.

455

456 Figure 2. Viral culture and PCR cycle count/viral load, by day since symptom onset or first PCR confirmed  
457 diagnosis.

458

459 Figure 3. Duration of infectivity as indicated by viral culture and corresponding PCR cycle counts/log  
460 copies among transplant recipients.

461

462 **List of supplementary files.**

463

464 Supplementary file. Literature search strategy.

465

466 Supplementary file. List of excluded studies, with reasons.

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493



494 **Table 1.** Characteristics of transplant patients in included studies.

495

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
Alshukairi 2021	Pt1: 34 yr F Pt2: 71 yr M Pt3: 75 yr M Pt4: 26 yr M Pt5: 38 yr F	Pt1: cardiac, in 2014, tacrolimus, MMF, prednisolone Pt2: renal, in 2014, tacrolimus, MMF, prednisolone, DM, HTN, CAD Pt3: renal, in 2014, tacrolimus, MMF and prednisolone, HTN Pt4: renal, in 2018, tacrolimus, MMF, prednisolone, DM Pt5: renal in 2014, tacrolimus, AZA, prednisolone, APS & hypothyroidism.	Pt1: Severe pneumonia; Pt2: pneumonia Pt3: pneumonia Pt4: pneumonia Pt5: upper RTI	Pt1: high-flow nasal cannula Pt2: low-flow cannula Pt3: low-flow cannula Pt4: oxygen not required Pt5: no cannula
Benotmane I 2021	14 M, 2 F, median age 63.3 yrs. Pts with at least two positive for SARS-CoV-2 NP swabs (of which one collected at least 7 days after symptom onset) during the follow-up period were eligible for inclusion	16 kidney transplant recipients; median time from transplant 3.8 yrs.  Antithymocyte globulin: 8/16; anti-CD25: 8/16; tacrolimus: 10/16; ciclosporin: 3/16; MMF/MPA: 14/16; mTOR inhibitors: 2/16; steroids: 10/16; belatacept: 2/16	All 16 hospitalized for symptomatic COVID-19 between 4 March and 15 April 2020	lopinavir/ritonavir: 1/16; hydroxychloroquine: 8/16; tocilizumab: 2/16
Decker A 2020	62 yr M	Heart transplant Nov 2019; subsequently pneumonia and acute respiratory distress syndrome; intermittent renal replacement therapy. Cyclosporine A	1 March 2020 onset of symptoms and +ve PCR; mild symptoms, no cardiorespiratory decline,	hydroxychloroquine (400mg b.i.d. + 200mg b.i.d.) from day 7 to 14

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
		(target range 135 ± 30 ng/mL), mycophenolate mofetil 500 mg b.i.d., prednisone 10 mg q.d. + cotrimoxazole and due to cytomegalovirus high-risk constellation (D + R-), ganciclovir for 4 months post-transplantation, then valganciclovir prophylaxis.	several weeks +ve.	
Lang C 2020	44 yr old F with mild untreated psoriatic arthritis and idiopathic CD4 lymphocytopenia	Bilateral lung transplant day 58 after admission for Covid-19. Subsequently, standard triple immunosuppression was initiated, including tacrolimus, mycophenolate mofetil, and steroids; also 6 additional treatment cycles of immunoabsorption and antithymocyte globulin.	Day 0 admitted with fever, cough, +ve NP RT-PCR. Day 6 to ICU & intubation; day 13 ECMO. Day 52 preparation begun for transplant: immunoabsorption therapy; day 58 bilateral lung transplant performed. Transferred to non ICU ward day 121.	Immunoglobulin s, tocilizumab & lopinavir. Day 6 to ICU & intubation; day 13 ECMO. Bilateral lung transplant
Niess 2020	56 yr M patient listed for liver transplantation with a Model For End-Stage Liver Disease Score of 19 points due to cryptogenic cirrhosis and a	admission for liver transplant: 18/3/2020 positive to COVID-19 screening on 25/3/2021 after 31-32 days: PCR negative + seroconversion after 36 days of symptom onset and 21		

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
	history of hepatitis B	days after seroconversion: transplant; tacrolimus (to target of 4 to 7 ng/ml) + steroids		
Niyonkuru M 2021	<p>Pt1: 66 yr M, recent liver transplant</p> <p>Pt2: 70 yr M, previous bone marrow transplant for multiple myeloma</p>	<p>Pt1: fatigue and tachypnea, hospital admission, tested positive for SARS-CoV-2</p> <p>Pt2: pacemaker. Lenalidomide 25 mg daily. elevated CRP concentration (130 mg/L). Nocardia Farcinica was detected in blood cultures and pus from abscesses on the left leg. Trans-esophageal echocardiography showed vegetation on the pacemaker electrode.</p>	<p>Pt1 day 0 +ve test. Symptom onset day 5, diminished taste and smell; day 12 additional symptoms; day 14 hospital admission. On day 12 from symptom onset transferred to the ICU for non invasive ventilation.</p> <p>Pt2 admitted on October 21 due to fever and elevated CRP concentration (130 mg/L) because of systemic infection due to pacemaker contamination; periodic screening during admission; positive by week 4, always asymptomatic of COVID-19.</p>	<p>Pt1: In ICU, non invasive ventilation, IV dexamethasone 6 mg daily and remdesivir: 200 mg the first day and 100 mg the following 4 days.</p> <p>Pt2: no COVID-19 treatment (asymptomatic)</p>

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
Rajakumar 2021	<p>Two cardiac transplant recipients (&lt;3 months post-transplant); Pt1: 56 yr F; history of dilated cardiomyopathy with end-stage heart failure, type-2 diabetes mellitus, hypothyroidism, osteoporosis, and anemia.</p> <p>Pt2: 33 yr F with a history of end-stage heart failure 2ndary to congenital heart disease, liver cirrhosis &amp; kidney disease.</p>	<p>Pt1: orthotopic heart transplant with antithymocyte globulin induction &amp; standard triple immunosuppressive therapy &amp; was discharged 30 days later.</p> <p>Pt2: orthotopic heart transplant with antithymocyte globulin induction therapy, discharged 4 weeks later.</p> <p>Pt1 and Pt2: prednisone, tacrolimus, and mycophenolate mofetil, and standard prophylactic medications</p>	<p>NP swabs (&amp; saliva &amp; clinical &amp; environmental samples) were collected at regular intervals beginning shortly after admission.</p> <p>Pt 1: 5 days post-discharge, rehospitalized following community exposure to COVID-19. Nasal stuffiness &amp; discharge, sneezing, fatigue &amp; cough developed on admission day 4; NP swab +ve for SARS-CoV-2. All symptoms except fatigue resolved by day 12. Dyspnea, cough &amp; hypoxia then developed on day 15; chest radiograph revealed new bibasilar interstitial infiltrates. Discharged day 44.</p> <p>Pt2: tested +ve</p>	<p>Pt1: after day 15, corticosteroids &amp; antimicrobials initiated for presumptive COVID-19 pneumonitis &amp; superimposed bacterial pneumonia; day 21 O2 requirements increased significantly. Despite discontinuation of MMF &amp; reduction of tacrolimus, cultivatable viral loads increased in the NP &amp; saliva; chest radiograph &amp; clinical condition deteriorated; mechanical ventilation considered. 10-day course of remdesivir initiated day 27. Clinical condition &amp; chest radiograph improved; O2 discontinued day 32; discharged day 44.</p> <p>Pt2: intubation.</p>

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
			<p>for SARS-CoV-2 shortly after discharge, readmitted 1 week later with progressive dyspnea &amp; hypoxemia requiring intubation.</p> <p>Significant viable virus burdens were noted in the NP swab (&amp; saliva, &amp; a used face cloth) 16 days after initial SARS-CoV-2 positivity. 5-day course remdesivir initiated followed by clinical recovery &amp; discharge 7 days later.</p>	<p>MMF dose was reduced; dexamethasone &amp; antimicrobials initiated. MMF was subsequently held &amp; later restarted when an echocardiogram demonstrated a reduction in left ventricular systolic function, suggesting acute graft rejection.</p> <p>Pt1: 10-day course of remdesivir from day 27 to day 37 from hospital admission; improvement and subsequent discharge on day 44</p> <p>Pt2: 5-day course remdesivir, improvement and discharge 7 days later</p>
Tarhini 2021	71yr European M	Cardiac transplant, also diabetes mellitus & chronic kidney disease; prednisone, mycophenolic acid, belatacept	15 April 2020 hospitalized for asthenia, dry cough, myalgia, and low-grade fever for 1 week. No	At readmission, treated in ICU for cardiac decompensation due to underlying respiratory

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
			<p>dyspnea or O2 need. +ve on admission and day 14 with &lt;10% Covid-19 involvement on CT scan. Discharged day 39 after clinical improvement, despite persistent +ve PCR at day 32 (21 Ct). 23 June readmitted with dry cough, dyspnea, and O2 requirement.</p>	<p>infection. [Unclear what happened after this; last test day 121 &amp; culture +ve at day 103, negative serology throughout]</p>
Weigang 2021	58 yr M	<p>kidney transplant, also CHD, arterial hypertension, hyperlipidemia, obesity; basiliximab (20mg, day 0 and day 4 post-transplantation) and prednisone (250mg at day 0, 125 mg day 1, 50mg day 2 to 5, 20mg day 6 to 10, then 15 mg/day). Additionally tacrolimus (10mg day 0, 8mg day 1, 5.5mg day 2, 5mg day 3 and 4, then 4mg/day) and Mycophenolate mofetil (2000mg/day). Maintenance immunosuppression consisted of tacrolimus (4 to 6mg/day), mycophenolate mofetil</p>	<p>March 2020, mild respiratory symptoms &amp; tested positive for SARS-CoV-2 for over 145 days; discharged on day 72 for home quarantine; re-hospitalized at day 106 to 126 due to another kidney transplant failure. Days 140 to 149 treated with remdesivir; subsequent PCR tests negative &amp; virus isolation negative.</p>	<p>Ivermectin 4 day course (33mg/day, day 56 to 60); 10 day course remdesivir (200 mg on day 140, then 100 mg/daily, day 141 to 149)</p>

Study ID	Participants (data extracted for transplant patients)	Transplant, immunosuppressive treatment & comorbidities	Clinical course of COVID-19 infection	COVID-19 treatments
		(2,000mg/day), and prednisone (10 to 20mg/day)		

496

497 Abbreviations:

498 APS = anti-phospholipid syndrome

499 AZA = azathioprine

500 CAD = coronary artery disease

501 DM = diabetes mellitus

502 HTN = hypertension

503 MMF = mycophenolate mofetil

504 NP = nasopharyngeal

505 Pt = patient

506 RTI = respiratory tract infection

507 RT-PCR = reverse transcriptase polymerase chain reaction

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532 **Table 2.** Quality of included studies.  
533

Study ID	Were the criteria for diagnosing a case clearly reported and appropriate?	Was the reporting of patient/ population characteristics adequate?	Was the study period, including follow-up, sufficient?	Were the methods used to obtain RT-PCR results replicable and appropriate?	Were the methods used to obtain viral culture results replicable and appropriate?
Alshukairi 2021	Unclear*	No**	Yes	Yes	Unclear
Benotmane I 2021	Yes	Yes	Yes	Yes	No***
Decker A 2020	No	Yes	Yes	Unclear	Unclear
Lang C 2020	Yes	Yes	Yes	Unclear	Unclear
Niess 2020	Yes	Yes	Yes	Yes	Unclear
Niyonkuru M 2021	No*	Yes	Yes	Yes	Yes
Rajakumar 2021	Yes	Yes	Yes	Yes	Yes
Tarhini 2021	Yes	Yes	Yes	Yes	Yes
Weigang 2021	Yes	Yes	Yes	Yes	Yes

534  
535 \*case definition unclear, article reports positive RT-PCR, but Ct cut-off not reported.

536 \*\* data on clinical symptoms lacking

537 \*\*\*The cell line used was not one that is demonstrated to support SARS-CoV-2 growth. Therefore the  
538 cell culture results are not reliable.

539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550



**Table 3.** PCR cycle counts/log copies and viral culture results of included studies.

Study ID	Symptoms, days reported	RT-PCR Cycle count/log copies results	Viral culture results (days)
Alshukairi 2021	NR no viral culture at admission/onset of symptoms	Pt1: D3: positive, Ct NA, D26: positive, 22.87 Pt2: D3: positive, 11.58; D17: positive, 23.12 Pt3: D6: positive, 8.82, D19: positive, 13.88 Pt4: D4: positive, 10.38; D12: positive, 27.57 Pt5: D1: positive, 2.8, D9: positive, 14.84	Pt1: D26: negative Pt2: D17: negative Pt3: D19: negative Pt4: D12: negative Pt5: D9: negative
Benotmane I 2021		Patient 6: D23: Ct > 30; D29: Ct > 35 Patient 7: D38: Ct > 35 Patient 8: D28: Ct > 30  Patient 11: D27: Ct > 30	Pt1: D5, D14: negative; Pt2: D21, D29: negative; Pt3: D25, D39: negative Pt4: D2: positive, D9, D16, D35: negative Pt5: D1, D8: positive; D23, D30: negative Pt6: D6, D9, D23, D29: positive Pt7: D7, D38: positive Pt8: D1: negative, D8, D28: positive Pt9: D11: negative, D30: negative Pt10: D2, D8: negative Pt11: D11, D27: positive Pt12: D17, D27: negative Pt13: D2, D9: positive; D31: negative Pt14: D3, D19: negative Pt15: D4, D17: negative Pt16: D20: positive, D30: negative.
Decker A 2020	Mild symptoms. Day 0: transient episode of fever & sore throat ; day 7 temperature increase; no clinical symptoms after day 20.	PCR +ve on days 1, 5, 7, 11, 18, 21, 25, 28, 33, and still on day 35 PCR remained positive on day 35 with copy numbers similar to the onset of infection. Concurrent with the second onset of fever there was an increased viral load after day 7 that slowly returned to the level of infection onset.	Viral culture +ve at day 18 and day 21 post-onset of symptoms.

Lang C 2020	Admitted with fever & cough becoming severe and life threatening leading to bilateral lung transplant.	Day 0, Ct 27; Day 17, Ct 21; Day 23, Ct 23; Day 19, Ct 32; Day 31, Ct 32; Day 36, Ct 29; Day 48, Ct 39; Day 53, Ct 34; Day 59, Ct 33; Day 61, PCR negative; Day 62, Ct 36; Day 62, PCR negative; Day 64, PCR negative; Day 65, Ct 36; Day 66, Ct 39; Day 69, Ct 39; Day 70, PCR negative; Day 72, PCR negative; Day 74, PCR negative; Day 76, PCR negative; Day 95, PCR negative;	Samples cultured from day 48 and day 65; both negative by cell culture.
Niess 2020	Mild symptoms of malaise and a dry cough	day 0: positive but asymptomatic day 8, 12, 19, 22 - positive PCR day 31, 32 - negative PCR day 49, 55, 60 - positive PCR day 58, 63, 64 - negative PCR results	Positive pre-transplant PCRs were not confirmed by cell cultures  4 negative viral cell culture results from samples taken on days 49, 54, 60 and 69  (* )
Niyonkuru M 2021	Pt1: fatigue and tachypnea, then ventilation required.  Pt2: asymptomatic for COVID-19.	Pt1: day 15 from 1st positive PCR/day 3 from symptoms onset: Cq 21.7; day 21 from 1st positive PCR/day 9 from symptoms onset: Cq 19.21; day 43 from 1st positive PCR/day 13 from symptoms onset Cq 35.45  Pt2: day 9 from 1st positive PCR: Cq: 22.33; day 12 from 1st positive PCR Cq 22.57; day 14 from 1st positive PCR: Ct approx 33.5; day 18 from 1st positive PCR: PCR negative.	Pt1: day 15 from 1st positive PCR/day 3 from symptoms onset viral culture at 61,277 PFU/swab; day 21 from 1st positive PCR/day 9 from symptoms onset viral culture at 256,410 PFU/swab; day 22 from 1st positive PCR/day 13 from symptoms onset viral culture negative.  Pt2: day 9 from 1st positive PCR: culture positive with 11082 PFU/swab; day 12 from 1st positive PCR: culture positive with PFU 55944/swab; day 14 from 1st positive PCR: culture negative.
Rajakumar 2021		Pt 1: hospital admission, positive PCR day 4 post-symptom onset Day 4: N gene Ct 16, E gene Ct 19 Day 12: N gene Ct 13, E gene Ct 20 Day 20: N gene Ct 14, E gene Ct 19 Day 27: N gene Ct 15, E gene Ct 21	Pt1 Viral culture Day 4: positive Day 12: positive Day 20: positive Day 27: positive

		<p>Day 32: N gene Ct 32, E gene Ct 28 Day 60: N gene Ct 30, E gene Ct 35</p> <p>Pt 2: Day 16: N gene Ct 14, E gene Ct 20 Day 22: N gene Ct 25, E gene Ct 33 Day 25: N gene Ct 25, E gene 29 Day 42: N gene Ct 29, E gene Ct 37 Day 51: N gene Ct 37, E gene Ct 39</p>	<p>Day 32: negative Day 60: negative</p> <p>Pt 2: Viral culture Day 16: positive Day 22: negative Day 25: negative Day 42: negative Day 51: negative</p>
Tarhini 2021	Severe infection requiring intensive care	<p>Day 6: Ct=25, Day 16: Ct=24 Day 32: Ct=20 Day 78: Ct=34 Day 80: Ct=24 Day 91: Ct=28 Day 103: Ct=23 Day 109: Ct=18 Day 120: Ct=26 Day 132: Ct=40+ (negative) Day 136: Ct=40+ (negative)</p> <p>(*)</p>	<p>Day 6: culture negative Day 16: culture negative Day 80: culture negative Day 91: culture negative Day 103: culture positive Day 111: culture negative Day 120: culture negative</p> <p>(*)</p>
Weigang 2021	Mild respiratory symptoms for over 145 days	<p>38 PCR tests: days 0, 6, 10, 14, 16, 21, 24, 27, 31, 34, 38, 42, 45, 46, 49, 52, 56, 58, 63, 65, 71, 105, 113, 115, 119, 122, 126, 140, 143, 145, 146, 149, 150, 154, 161, 167, 174, 189. 38</p> <p>Ct values: 25, 16, 19, 19, 25, 23, 18, 26, 20, 17, 31, 27, 27, 50, 27, 28, 25, 28, 27, 29, 30, 23, 34, 29, 31, 31, 36, 26, 29, 34, 39, 45, 45, 34, 45, 45, 45, 45.</p>	<p>27 cell culture tests, days: 0, 6, 10, 14, 16, 21, 24, 27, 31, 34, 38, 42, 45, 49, 52, 56, 58, 63, 65, 71, 105, 106, 113, 115, 119, 140, 154; 27 results: -, +, +, +, -, +, +, +, +, -, -, -, -, -, -, -, +, -, -, -, -, -, (i.e. positive on days 6, 10, 14, 21, 24, 27, 31, 34, 105)</p>

(\*) Numbers have been read from a figure in the published article and may not be an accurate estimate.

553  
554  
555  
556

Ct = cycle threshold  
D = day

557 NR = not reported  
558 NA = not available  
559 Pt = patient  
560 RT-PCR = reverse transcriptase polymerase chain reaction  
561  
562

563  
564

Figure 1. PRISMA flow chart of study screening for inclusion.




Figure 2. SARs-CoV-2 culture results in transplant patients from symptom onset




Figure 3a. Timings of positive culture results in Transplant Patients by duration of symptoms and Ct results

■ Negative Culture  
■ Positive Culture  
 Number equals RT-PCR Cycle Threshold





Figure 3b. Timings of positive culture results in Transplant Patients by duration of symptoms and Ct results in Tarhini et al. [8]




■ Negative Culture  
■ Positive Culture  
 Number equals RT-PCR Cycle Threshold





Figure 3d. Timings of positive culture results in Transplant Patients by duration of symptoms and log10 copieas/ml results in Decker et al. [9]



- Negative Culture
- Positive Culture
- Number equals RT-PCR Cycle Threshold